Prophylactic central neck lymphadenectomy in high risk patients with T1 or T2 papillary thyroid carcinoma: is it useful?

25.00

COD: 05_2201_225-229 Categorie: ,

Daniele Delogu, Ilia Patrizia Pisano, Carlo Pala, Fabio Pulighe, Salvatore Denti, Antonio Cossu, Mario Trignano

Ann. Ital. Chir., 2014 85: 225-229

La mia nuova descrizione qui!

Price of a print issue €25.00

INTRODUCTION: The aim of this study was to evaluate the role of prophylactic central neck lymph node dissection in
high risk patients with T1 or T2 papillary thyroid cancer.
MATERIALS AND METHODS: Seventy-three patients who had undergone total thyroidectomy for papillary thyroid cancer
smaller than 4cm, without cervical lymphadenopathy and prophylactic central neck lymph node dissection were included.
Patients were divided in two groups: low risk patients (group A) and high risk patients (group B). High risk patients
were considered those with at least one of the followings: male sex, age ≥ 45 years, and extracapsular or extrathyroid
disease. Statistical significant differences in persistent disease, recurrence and complications rates between the two groups
were studied.
RESULTS: Persistence of the disease was observed in one case in group A (5.9%) and in three cases in group B (5.4%),
while thyroid cancer recurrence was registered in zero and two (3.6%) cases respectively. One single case (5.9%) of transitory
recurrent laryngeal nerve damage was reported in group A and none in group B, while transitory hypoparathyroidism
was observed in 2 (3.6%) patients in group A, and 1 (1.8%) patient in group B. Permanent recurrent laryngeal
nerve damage was observed in one patient in group A, while permanent hypoparathyroidism was registered in one
case in group B. Logistic regression evidenced that multifocality was the only risk factor significantly related to persistence
of disease and recurrence.
CONCLUSIONS: Our results suggests that prophylactic central neck lymph node dissection can be safely avoided in patients
with T1 or T2 papillary thyroid cancer, except in those with multifocal disease.

0

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.

Chiudi